News 
Market Data 
Discover
db7
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hi bb, what is your take on this chart? break of 50 day? bought a small position today on pr and chart
in LAMP @ .025, LAM IPM Wound Gel(TM) Receives Regulatory Approval for Panama
Wednesday September 14, 7:00 am ET
LEWISTON, New York, September 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC: LAMP - News; Frankfurt: LAM - News; Berlin: LAM - News), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received a regulatory approval to market and sell its patented and proprietary LAM IPM Wound Gel(TM) in the Republic of Panama. The approval was granted Ministerio de Salud, Direccion Nacional de Farmacia y Drogas (the Panamanian Ministry of Health), registration number "61523".
ADVERTISEMENT
Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., LAM's distribution partner for Central America, stated, "We are pleased to have another country in our distribution territory in which the LAM IPM Wound Gel(TM) has been approved. Based on our marketing feedback to-date, we are confident that Panama will quickly become a key component in our regional sales strategy."
Mr. Pedro Riley, President of Tecno Farma of aQva Pharmaceutical in Panama added, "LAM IPM Wound Gel is being received very well by all Panamanian doctors and other medical professionals to whom the product has been introduced. We have been holding conferences and seminars throughout the country in anticipation of the approval. We have a reason to believe that the Gel will become one of the leading would healing products in Panama." Mr. Riley continued," On September 16 and 17, several of our doctor users of the LAM IPM Wound Gel(TM) will be presenting their patient results with the Gel at the Panama National Geriatric Association Conference. This will further enhance the credibility of this exceptional wound healing product."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "We would like to thank again our partners at aQva for their hard work and congratulate them on obtaining the approval for the LAM IPM Gel(TM) in Panama. We are very excited about the rapidly increasing market exposure of the Gel in Central America and are fully behind aQva's marketing strategy in the region."
About LAM Pharmaceutical, Corp.
For more information about L.A.M. Pharmaceutical, Corp., please see our web site at www.lampharm.com .
About aQva Pharmaceuticals
aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Contact:
Stephanie Carrington (Investors/Media)
+1-646-536-7017
The Ruth Group
--------------------------------------------------------------------------------
Source: LAM Pharmaceutical Corp.
in LAMP @ .025, LAM IPM Wound Gel(TM) Receives Regulatory Approval for Panama
Wednesday September 14, 7:00 am ET
LEWISTON, New York, September 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC: LAMP - News; Frankfurt: LAM - News; Berlin: LAM - News), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received a regulatory approval to market and sell its patented and proprietary LAM IPM Wound Gel(TM) in the Republic of Panama. The approval was granted Ministerio de Salud, Direccion Nacional de Farmacia y Drogas (the Panamanian Ministry of Health), registration number "61523".
ADVERTISEMENT
Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., LAM's distribution partner for Central America, stated, "We are pleased to have another country in our distribution territory in which the LAM IPM Wound Gel(TM) has been approved. Based on our marketing feedback to-date, we are confident that Panama will quickly become a key component in our regional sales strategy."
Mr. Pedro Riley, President of Tecno Farma of aQva Pharmaceutical in Panama added, "LAM IPM Wound Gel is being received very well by all Panamanian doctors and other medical professionals to whom the product has been introduced. We have been holding conferences and seminars throughout the country in anticipation of the approval. We have a reason to believe that the Gel will become one of the leading would healing products in Panama." Mr. Riley continued," On September 16 and 17, several of our doctor users of the LAM IPM Wound Gel(TM) will be presenting their patient results with the Gel at the Panama National Geriatric Association Conference. This will further enhance the credibility of this exceptional wound healing product."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "We would like to thank again our partners at aQva for their hard work and congratulate them on obtaining the approval for the LAM IPM Gel(TM) in Panama. We are very excited about the rapidly increasing market exposure of the Gel in Central America and are fully behind aQva's marketing strategy in the region."
About LAM Pharmaceutical, Corp.
For more information about L.A.M. Pharmaceutical, Corp., please see our web site at www.lampharm.com .
About aQva Pharmaceuticals
aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Contact:
Stephanie Carrington (Investors/Media)
+1-646-536-7017
The Ruth Group
--------------------------------------------------------------------------------
Source: LAM Pharmaceutical Corp.
in LAMP @ .025, LAM IPM Wound Gel(TM) Receives Regulatory Approval for Panama
Wednesday September 14, 7:00 am ET
LEWISTON, New York, September 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC: LAMP - News; Frankfurt: LAM - News; Berlin: LAM - News), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received a regulatory approval to market and sell its patented and proprietary LAM IPM Wound Gel(TM) in the Republic of Panama. The approval was granted Ministerio de Salud, Direccion Nacional de Farmacia y Drogas (the Panamanian Ministry of Health), registration number "61523".
ADVERTISEMENT
Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., LAM's distribution partner for Central America, stated, "We are pleased to have another country in our distribution territory in which the LAM IPM Wound Gel(TM) has been approved. Based on our marketing feedback to-date, we are confident that Panama will quickly become a key component in our regional sales strategy."
Mr. Pedro Riley, President of Tecno Farma of aQva Pharmaceutical in Panama added, "LAM IPM Wound Gel is being received very well by all Panamanian doctors and other medical professionals to whom the product has been introduced. We have been holding conferences and seminars throughout the country in anticipation of the approval. We have a reason to believe that the Gel will become one of the leading would healing products in Panama." Mr. Riley continued," On September 16 and 17, several of our doctor users of the LAM IPM Wound Gel(TM) will be presenting their patient results with the Gel at the Panama National Geriatric Association Conference. This will further enhance the credibility of this exceptional wound healing product."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "We would like to thank again our partners at aQva for their hard work and congratulate them on obtaining the approval for the LAM IPM Gel(TM) in Panama. We are very excited about the rapidly increasing market exposure of the Gel in Central America and are fully behind aQva's marketing strategy in the region."
About LAM Pharmaceutical, Corp.
For more information about L.A.M. Pharmaceutical, Corp., please see our web site at www.lampharm.com .
About aQva Pharmaceuticals
aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Contact:
Stephanie Carrington (Investors/Media)
+1-646-536-7017
The Ruth Group
--------------------------------------------------------------------------------
Source: LAM Pharmaceutical Corp.
in LAMP @ .025, LAM IPM Wound Gel(TM) Receives Regulatory Approval for Panama
Wednesday September 14, 7:00 am ET
LEWISTON, New York, September 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC: LAMP - News; Frankfurt: LAM - News; Berlin: LAM - News), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received a regulatory approval to market and sell its patented and proprietary LAM IPM Wound Gel(TM) in the Republic of Panama. The approval was granted Ministerio de Salud, Direccion Nacional de Farmacia y Drogas (the Panamanian Ministry of Health), registration number "61523".
ADVERTISEMENT
Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., LAM's distribution partner for Central America, stated, "We are pleased to have another country in our distribution territory in which the LAM IPM Wound Gel(TM) has been approved. Based on our marketing feedback to-date, we are confident that Panama will quickly become a key component in our regional sales strategy."
Mr. Pedro Riley, President of Tecno Farma of aQva Pharmaceutical in Panama added, "LAM IPM Wound Gel is being received very well by all Panamanian doctors and other medical professionals to whom the product has been introduced. We have been holding conferences and seminars throughout the country in anticipation of the approval. We have a reason to believe that the Gel will become one of the leading would healing products in Panama." Mr. Riley continued," On September 16 and 17, several of our doctor users of the LAM IPM Wound Gel(TM) will be presenting their patient results with the Gel at the Panama National Geriatric Association Conference. This will further enhance the credibility of this exceptional wound healing product."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "We would like to thank again our partners at aQva for their hard work and congratulate them on obtaining the approval for the LAM IPM Gel(TM) in Panama. We are very excited about the rapidly increasing market exposure of the Gel in Central America and are fully behind aQva's marketing strategy in the region."
About LAM Pharmaceutical, Corp.
For more information about L.A.M. Pharmaceutical, Corp., please see our web site at www.lampharm.com .
About aQva Pharmaceuticals
aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Contact:
Stephanie Carrington (Investors/Media)
+1-646-536-7017
The Ruth Group
--------------------------------------------------------------------------------
Source: LAM Pharmaceutical Corp.
in 50k LAMP @ .025, LAM IPM Wound Gel(TM) Receives Regulatory Approval for Panama
Wednesday September 14, 7:00 am ET
LEWISTON, New York, September 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC: LAMP - News; Frankfurt: LAM - News; Berlin: LAM - News), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it received a regulatory approval to market and sell its patented and proprietary LAM IPM Wound Gel(TM) in the Republic of Panama. The approval was granted Ministerio de Salud, Direccion Nacional de Farmacia y Drogas (the Panamanian Ministry of Health), registration number "61523".
ADVERTISEMENT
Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., LAM's distribution partner for Central America, stated, "We are pleased to have another country in our distribution territory in which the LAM IPM Wound Gel(TM) has been approved. Based on our marketing feedback to-date, we are confident that Panama will quickly become a key component in our regional sales strategy."
Mr. Pedro Riley, President of Tecno Farma of aQva Pharmaceutical in Panama added, "LAM IPM Wound Gel is being received very well by all Panamanian doctors and other medical professionals to whom the product has been introduced. We have been holding conferences and seminars throughout the country in anticipation of the approval. We have a reason to believe that the Gel will become one of the leading would healing products in Panama." Mr. Riley continued," On September 16 and 17, several of our doctor users of the LAM IPM Wound Gel(TM) will be presenting their patient results with the Gel at the Panama National Geriatric Association Conference. This will further enhance the credibility of this exceptional wound healing product."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "We would like to thank again our partners at aQva for their hard work and congratulate them on obtaining the approval for the LAM IPM Gel(TM) in Panama. We are very excited about the rapidly increasing market exposure of the Gel in Central America and are fully behind aQva's marketing strategy in the region."
About LAM Pharmaceutical, Corp.
For more information about L.A.M. Pharmaceutical, Corp., please see our web site at www.lampharm.com .
About aQva Pharmaceuticals
aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Contact:
Stephanie Carrington (Investors/Media)
+1-646-536-7017
The Ruth Group
--------------------------------------------------------------------------------
Source: LAM Pharmaceutical Corp.
in QTEK @ .072, Quintek Technologies Current Fiscal Year Revenues Due Out by Sept. 30
Wednesday September 14, 8:06 am ET
Revenues Expected to Increase 300% and Exceed Projections
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 14, 2005 -- Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), a global provider of Business Process Outsourcing (BPO) and best-of-breed technology consulting services, announced today that the financial results for current fiscal year ended June 30, 2005 are due out by Sept. 30, 2005. Revenues are expected to come in ahead of previously disclosed projections and represent an increase of over 400% versus the previous year.
ADVERTISEMENT
In July of last year the company released projections for the year ending June 30, 2005 of $887,705. Quintek disclosed revenues of over $844,762 in the first nine months of FY 2005. For the fiscal year ending June 30, 2005 Quintek anticipates revenues of at least $1,242,787, representing an increase of over 300% versus the prior fiscal year. The revised projections represent a guidance increase of over 40% above the original forecast.
The Company expects to continue achieving strong growth while further penetrating the large and rapidly expanding market for Business Process Outsourcing (BPO) services. Forrester Research forecasts the BPO space will have grown from $19 billion in 2004 to more than $145 billion in 2008, a Compounded Annual Growth Rate (CAGR) of 66%. Quintek has experienced a quarterly growth over the past several quarters.
"The Company has made progress within all of our targeted markets," stated Robert Steele, CEO of Quintek. "We continue to execute and deliver on long-term contracts with marquis customers and build relationships with our partners. Building upon the foundation we have created over the past 18 months, the Company should achieve critical mass, leading to profitability and an increase in shareholder value."
A summary of important business developments includes:
-- The development of Quintek's outsourced Accounts Payable (AP) service,
which can benefit almost any major corporation. As a result of increased
corporate reporting requirements spurred on by the Sarbanes-Oxley Act of
2002, demand is on the rise for solutions such as this.
-- Last fall Quintek entered into an agreement with a $3 billion provider
of industrial and institutional applications. Quintek provides a suite of
services that streamline and outsource this company's accounts payable (AP)
function.
-- The Company entered into an open agreement with Single Source Partners
(SSP) in April 2004 to advance sales in the mortgage industry.
-- Last fall, after identification by SSP, Quintek began providing
services to a Fortune 10 lending institution, with reported annual revenues
of over $20 billion. The Company has seen continued growth in revenues
within this account.
-- In July 2005, Quintek executed an Exclusive Sales and Marketing
Agreement with SSP targeting approximately $15 million in new business over
the next twelve months.
-- In the spring of 2004, the Company entered into an agreement with a
nationally recognized business solutions and overnight delivery company, to
provide outsourced services to their customers.
-- In February 2005, the Company began work on its first multi-year
agreement through the above mentioned relationship. Under this agreement
Quintek is providing services in Thousand Oaks, CA, for a leading life
sciences and biotechnology company.
-- Through a subcontracting agreement with a healthcare technologies
integrator, Quintek has been providing imaging service for over 12 months
for a major medical center in Los Angeles, CA.
Additionally, Quintek announced the creation of the Sapphire Consulting Services, Inc. business unit, a Supply Chain Management (SCM) consulting company that is a wholly owned subsidiary of Quintek. Sapphire is rapidly contributing to the overall growth of Quintek and it is expected to continue to add new customers and create new revenue channels. Sapphire has already identified a pipeline of potential business dollars with major customers across all markets that exceed $30 million.
Andrew Haag, Quintek CFO, commented, "We plan to capitalize on our success over the past year and a half by aggressively continuing to build our Company." He added, "As we grow we will expand our awareness with financial institutions and investors, with the goal of adding shareholder value."
About Quintek Technologies, Inc.
Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), through its wholly owned subsidiaries Quintek Services, Inc. (QSI), and Sapphire Consulting Services, Inc., provides services to enable Fortune 500 and Global 2000 corporations to reduce costs and maximize revenues.
QSI delivers Business Process Outsourcing (BPO) services and solutions that enable companies to secure and manage their key data processing demands with optimal efficiency and minimal costs. As a next-generation technology company, Quintek is unhindered by outdated information technology systems, and thus is able to deploy best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a provider of IT market intelligence, forecasts 13% annual growth for the BPO industry through 2005, when the market is projected to reach $248 billion.
Sapphire Consulting Services, Inc. offers a broad range of supply chain management consulting services. Sapphire assists organizations to create a higher level of customer satisfaction, enhance supply chain capability and achieve consistent competitive advantage through reduced product cost, reduced inventory investment and improved supply chain security. A study by IDC found the SCM services market will expand from $26.1 billion in 2002 to $40.5 billion in 2007, representing a five-year compound annual growth rate (CAGR) of 9.2%.
For more information, visit http://www.quintek.com.
Safe Harbor Statement
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act'), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Quintek to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Quintek's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2004 and any subsequent reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Quintek assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, inability to timely develop of products or services, inability to deliver products or services when ordered, inability of potential customers to pay for ordered products or services, and political and economic risks inherent in domestic and international trade.
Contact:
CONTACTS:
Quintek Technologies, Inc.
Andrew Haag
Chief Financial Officer
(714) 848-7741, Ext. 14
Email Contact
Communications:
Cinapsys, Inc.
Mark Moline
(949) 497-6684
Email Contact
in QTEK @ .072, Quintek Technologies Current Fiscal Year Revenues Due Out by Sept. 30
Wednesday September 14, 8:06 am ET
Revenues Expected to Increase 300% and Exceed Projections
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 14, 2005 -- Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), a global provider of Business Process Outsourcing (BPO) and best-of-breed technology consulting services, announced today that the financial results for current fiscal year ended June 30, 2005 are due out by Sept. 30, 2005. Revenues are expected to come in ahead of previously disclosed projections and represent an increase of over 400% versus the previous year.
ADVERTISEMENT
In July of last year the company released projections for the year ending June 30, 2005 of $887,705. Quintek disclosed revenues of over $844,762 in the first nine months of FY 2005. For the fiscal year ending June 30, 2005 Quintek anticipates revenues of at least $1,242,787, representing an increase of over 300% versus the prior fiscal year. The revised projections represent a guidance increase of over 40% above the original forecast.
The Company expects to continue achieving strong growth while further penetrating the large and rapidly expanding market for Business Process Outsourcing (BPO) services. Forrester Research forecasts the BPO space will have grown from $19 billion in 2004 to more than $145 billion in 2008, a Compounded Annual Growth Rate (CAGR) of 66%. Quintek has experienced a quarterly growth over the past several quarters.
"The Company has made progress within all of our targeted markets," stated Robert Steele, CEO of Quintek. "We continue to execute and deliver on long-term contracts with marquis customers and build relationships with our partners. Building upon the foundation we have created over the past 18 months, the Company should achieve critical mass, leading to profitability and an increase in shareholder value."
A summary of important business developments includes:
-- The development of Quintek's outsourced Accounts Payable (AP) service,
which can benefit almost any major corporation. As a result of increased
corporate reporting requirements spurred on by the Sarbanes-Oxley Act of
2002, demand is on the rise for solutions such as this.
-- Last fall Quintek entered into an agreement with a $3 billion provider
of industrial and institutional applications. Quintek provides a suite of
services that streamline and outsource this company's accounts payable (AP)
function.
-- The Company entered into an open agreement with Single Source Partners
(SSP) in April 2004 to advance sales in the mortgage industry.
-- Last fall, after identification by SSP, Quintek began providing
services to a Fortune 10 lending institution, with reported annual revenues
of over $20 billion. The Company has seen continued growth in revenues
within this account.
-- In July 2005, Quintek executed an Exclusive Sales and Marketing
Agreement with SSP targeting approximately $15 million in new business over
the next twelve months.
-- In the spring of 2004, the Company entered into an agreement with a
nationally recognized business solutions and overnight delivery company, to
provide outsourced services to their customers.
-- In February 2005, the Company began work on its first multi-year
agreement through the above mentioned relationship. Under this agreement
Quintek is providing services in Thousand Oaks, CA, for a leading life
sciences and biotechnology company.
-- Through a subcontracting agreement with a healthcare technologies
integrator, Quintek has been providing imaging service for over 12 months
for a major medical center in Los Angeles, CA.
Additionally, Quintek announced the creation of the Sapphire Consulting Services, Inc. business unit, a Supply Chain Management (SCM) consulting company that is a wholly owned subsidiary of Quintek. Sapphire is rapidly contributing to the overall growth of Quintek and it is expected to continue to add new customers and create new revenue channels. Sapphire has already identified a pipeline of potential business dollars with major customers across all markets that exceed $30 million.
Andrew Haag, Quintek CFO, commented, "We plan to capitalize on our success over the past year and a half by aggressively continuing to build our Company." He added, "As we grow we will expand our awareness with financial institutions and investors, with the goal of adding shareholder value."
About Quintek Technologies, Inc.
Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), through its wholly owned subsidiaries Quintek Services, Inc. (QSI), and Sapphire Consulting Services, Inc., provides services to enable Fortune 500 and Global 2000 corporations to reduce costs and maximize revenues.
QSI delivers Business Process Outsourcing (BPO) services and solutions that enable companies to secure and manage their key data processing demands with optimal efficiency and minimal costs. As a next-generation technology company, Quintek is unhindered by outdated information technology systems, and thus is able to deploy best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a provider of IT market intelligence, forecasts 13% annual growth for the BPO industry through 2005, when the market is projected to reach $248 billion.
Sapphire Consulting Services, Inc. offers a broad range of supply chain management consulting services. Sapphire assists organizations to create a higher level of customer satisfaction, enhance supply chain capability and achieve consistent competitive advantage through reduced product cost, reduced inventory investment and improved supply chain security. A study by IDC found the SCM services market will expand from $26.1 billion in 2002 to $40.5 billion in 2007, representing a five-year compound annual growth rate (CAGR) of 9.2%.
For more information, visit http://www.quintek.com.
Safe Harbor Statement
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act'), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Quintek to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Quintek's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2004 and any subsequent reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Quintek assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, inability to timely develop of products or services, inability to deliver products or services when ordered, inability of potential customers to pay for ordered products or services, and political and economic risks inherent in domestic and international trade.
Contact:
CONTACTS:
Quintek Technologies, Inc.
Andrew Haag
Chief Financial Officer
(714) 848-7741, Ext. 14
Email Contact
Communications:
Cinapsys, Inc.
Mark Moline
(949) 497-6684
Email Contact
in QTEK @ .072, Quintek Technologies Current Fiscal Year Revenues Due Out by Sept. 30
Wednesday September 14, 8:06 am ET
Revenues Expected to Increase 300% and Exceed Projections
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 14, 2005 -- Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), a global provider of Business Process Outsourcing (BPO) and best-of-breed technology consulting services, announced today that the financial results for current fiscal year ended June 30, 2005 are due out by Sept. 30, 2005. Revenues are expected to come in ahead of previously disclosed projections and represent an increase of over 400% versus the previous year.
ADVERTISEMENT
In July of last year the company released projections for the year ending June 30, 2005 of $887,705. Quintek disclosed revenues of over $844,762 in the first nine months of FY 2005. For the fiscal year ending June 30, 2005 Quintek anticipates revenues of at least $1,242,787, representing an increase of over 300% versus the prior fiscal year. The revised projections represent a guidance increase of over 40% above the original forecast.
The Company expects to continue achieving strong growth while further penetrating the large and rapidly expanding market for Business Process Outsourcing (BPO) services. Forrester Research forecasts the BPO space will have grown from $19 billion in 2004 to more than $145 billion in 2008, a Compounded Annual Growth Rate (CAGR) of 66%. Quintek has experienced a quarterly growth over the past several quarters.
"The Company has made progress within all of our targeted markets," stated Robert Steele, CEO of Quintek. "We continue to execute and deliver on long-term contracts with marquis customers and build relationships with our partners. Building upon the foundation we have created over the past 18 months, the Company should achieve critical mass, leading to profitability and an increase in shareholder value."
A summary of important business developments includes:
-- The development of Quintek's outsourced Accounts Payable (AP) service,
which can benefit almost any major corporation. As a result of increased
corporate reporting requirements spurred on by the Sarbanes-Oxley Act of
2002, demand is on the rise for solutions such as this.
-- Last fall Quintek entered into an agreement with a $3 billion provider
of industrial and institutional applications. Quintek provides a suite of
services that streamline and outsource this company's accounts payable (AP)
function.
-- The Company entered into an open agreement with Single Source Partners
(SSP) in April 2004 to advance sales in the mortgage industry.
-- Last fall, after identification by SSP, Quintek began providing
services to a Fortune 10 lending institution, with reported annual revenues
of over $20 billion. The Company has seen continued growth in revenues
within this account.
-- In July 2005, Quintek executed an Exclusive Sales and Marketing
Agreement with SSP targeting approximately $15 million in new business over
the next twelve months.
-- In the spring of 2004, the Company entered into an agreement with a
nationally recognized business solutions and overnight delivery company, to
provide outsourced services to their customers.
-- In February 2005, the Company began work on its first multi-year
agreement through the above mentioned relationship. Under this agreement
Quintek is providing services in Thousand Oaks, CA, for a leading life
sciences and biotechnology company.
-- Through a subcontracting agreement with a healthcare technologies
integrator, Quintek has been providing imaging service for over 12 months
for a major medical center in Los Angeles, CA.
Additionally, Quintek announced the creation of the Sapphire Consulting Services, Inc. business unit, a Supply Chain Management (SCM) consulting company that is a wholly owned subsidiary of Quintek. Sapphire is rapidly contributing to the overall growth of Quintek and it is expected to continue to add new customers and create new revenue channels. Sapphire has already identified a pipeline of potential business dollars with major customers across all markets that exceed $30 million.
Andrew Haag, Quintek CFO, commented, "We plan to capitalize on our success over the past year and a half by aggressively continuing to build our Company." He added, "As we grow we will expand our awareness with financial institutions and investors, with the goal of adding shareholder value."
About Quintek Technologies, Inc.
Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), through its wholly owned subsidiaries Quintek Services, Inc. (QSI), and Sapphire Consulting Services, Inc., provides services to enable Fortune 500 and Global 2000 corporations to reduce costs and maximize revenues.
QSI delivers Business Process Outsourcing (BPO) services and solutions that enable companies to secure and manage their key data processing demands with optimal efficiency and minimal costs. As a next-generation technology company, Quintek is unhindered by outdated information technology systems, and thus is able to deploy best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a provider of IT market intelligence, forecasts 13% annual growth for the BPO industry through 2005, when the market is projected to reach $248 billion.
Sapphire Consulting Services, Inc. offers a broad range of supply chain management consulting services. Sapphire assists organizations to create a higher level of customer satisfaction, enhance supply chain capability and achieve consistent competitive advantage through reduced product cost, reduced inventory investment and improved supply chain security. A study by IDC found the SCM services market will expand from $26.1 billion in 2002 to $40.5 billion in 2007, representing a five-year compound annual growth rate (CAGR) of 9.2%.
For more information, visit http://www.quintek.com.
Safe Harbor Statement
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act'), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Quintek to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Quintek's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2004 and any subsequent reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Quintek assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, inability to timely develop of products or services, inability to deliver products or services when ordered, inability of potential customers to pay for ordered products or services, and political and economic risks inherent in domestic and international trade.
Contact:
CONTACTS:
Quintek Technologies, Inc.
Andrew Haag
Chief Financial Officer
(714) 848-7741, Ext. 14
Email Contact
Communications:
Cinapsys, Inc.
Mark Moline
(949) 497-6684
Email Contact
in QTEK @ .072, Quintek Technologies Current Fiscal Year Revenues Due Out by Sept. 30
Wednesday September 14, 8:06 am ET
Revenues Expected to Increase 300% and Exceed Projections
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 14, 2005 -- Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), a global provider of Business Process Outsourcing (BPO) and best-of-breed technology consulting services, announced today that the financial results for current fiscal year ended June 30, 2005 are due out by Sept. 30, 2005. Revenues are expected to come in ahead of previously disclosed projections and represent an increase of over 400% versus the previous year.
ADVERTISEMENT
In July of last year the company released projections for the year ending June 30, 2005 of $887,705. Quintek disclosed revenues of over $844,762 in the first nine months of FY 2005. For the fiscal year ending June 30, 2005 Quintek anticipates revenues of at least $1,242,787, representing an increase of over 300% versus the prior fiscal year. The revised projections represent a guidance increase of over 40% above the original forecast.
The Company expects to continue achieving strong growth while further penetrating the large and rapidly expanding market for Business Process Outsourcing (BPO) services. Forrester Research forecasts the BPO space will have grown from $19 billion in 2004 to more than $145 billion in 2008, a Compounded Annual Growth Rate (CAGR) of 66%. Quintek has experienced a quarterly growth over the past several quarters.
"The Company has made progress within all of our targeted markets," stated Robert Steele, CEO of Quintek. "We continue to execute and deliver on long-term contracts with marquis customers and build relationships with our partners. Building upon the foundation we have created over the past 18 months, the Company should achieve critical mass, leading to profitability and an increase in shareholder value."
A summary of important business developments includes:
-- The development of Quintek's outsourced Accounts Payable (AP) service,
which can benefit almost any major corporation. As a result of increased
corporate reporting requirements spurred on by the Sarbanes-Oxley Act of
2002, demand is on the rise for solutions such as this.
-- Last fall Quintek entered into an agreement with a $3 billion provider
of industrial and institutional applications. Quintek provides a suite of
services that streamline and outsource this company's accounts payable (AP)
function.
-- The Company entered into an open agreement with Single Source Partners
(SSP) in April 2004 to advance sales in the mortgage industry.
-- Last fall, after identification by SSP, Quintek began providing
services to a Fortune 10 lending institution, with reported annual revenues
of over $20 billion. The Company has seen continued growth in revenues
within this account.
-- In July 2005, Quintek executed an Exclusive Sales and Marketing
Agreement with SSP targeting approximately $15 million in new business over
the next twelve months.
-- In the spring of 2004, the Company entered into an agreement with a
nationally recognized business solutions and overnight delivery company, to
provide outsourced services to their customers.
-- In February 2005, the Company began work on its first multi-year
agreement through the above mentioned relationship. Under this agreement
Quintek is providing services in Thousand Oaks, CA, for a leading life
sciences and biotechnology company.
-- Through a subcontracting agreement with a healthcare technologies
integrator, Quintek has been providing imaging service for over 12 months
for a major medical center in Los Angeles, CA.
Additionally, Quintek announced the creation of the Sapphire Consulting Services, Inc. business unit, a Supply Chain Management (SCM) consulting company that is a wholly owned subsidiary of Quintek. Sapphire is rapidly contributing to the overall growth of Quintek and it is expected to continue to add new customers and create new revenue channels. Sapphire has already identified a pipeline of potential business dollars with major customers across all markets that exceed $30 million.
Andrew Haag, Quintek CFO, commented, "We plan to capitalize on our success over the past year and a half by aggressively continuing to build our Company." He added, "As we grow we will expand our awareness with financial institutions and investors, with the goal of adding shareholder value."
About Quintek Technologies, Inc.
Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), through its wholly owned subsidiaries Quintek Services, Inc. (QSI), and Sapphire Consulting Services, Inc., provides services to enable Fortune 500 and Global 2000 corporations to reduce costs and maximize revenues.
QSI delivers Business Process Outsourcing (BPO) services and solutions that enable companies to secure and manage their key data processing demands with optimal efficiency and minimal costs. As a next-generation technology company, Quintek is unhindered by outdated information technology systems, and thus is able to deploy best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a provider of IT market intelligence, forecasts 13% annual growth for the BPO industry through 2005, when the market is projected to reach $248 billion.
Sapphire Consulting Services, Inc. offers a broad range of supply chain management consulting services. Sapphire assists organizations to create a higher level of customer satisfaction, enhance supply chain capability and achieve consistent competitive advantage through reduced product cost, reduced inventory investment and improved supply chain security. A study by IDC found the SCM services market will expand from $26.1 billion in 2002 to $40.5 billion in 2007, representing a five-year compound annual growth rate (CAGR) of 9.2%.
For more information, visit http://www.quintek.com.
Safe Harbor Statement
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act'), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Quintek to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Quintek's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2004 and any subsequent reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Quintek assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, inability to timely develop of products or services, inability to deliver products or services when ordered, inability of potential customers to pay for ordered products or services, and political and economic risks inherent in domestic and international trade.
Contact:
CONTACTS:
Quintek Technologies, Inc.
Andrew Haag
Chief Financial Officer
(714) 848-7741, Ext. 14
Email Contact
Communications:
Cinapsys, Inc.
Mark Moline
(949) 497-6684
Email Contact
in 17k QTEK @ .072, Quintek Technologies Current Fiscal Year Revenues Due Out by Sept. 30
Wednesday September 14, 8:06 am ET
Revenues Expected to Increase 300% and Exceed Projections
HUNTINGTON BEACH, CA--(MARKET WIRE)--Sep 14, 2005 -- Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), a global provider of Business Process Outsourcing (BPO) and best-of-breed technology consulting services, announced today that the financial results for current fiscal year ended June 30, 2005 are due out by Sept. 30, 2005. Revenues are expected to come in ahead of previously disclosed projections and represent an increase of over 400% versus the previous year.
ADVERTISEMENT
In July of last year the company released projections for the year ending June 30, 2005 of $887,705. Quintek disclosed revenues of over $844,762 in the first nine months of FY 2005. For the fiscal year ending June 30, 2005 Quintek anticipates revenues of at least $1,242,787, representing an increase of over 300% versus the prior fiscal year. The revised projections represent a guidance increase of over 40% above the original forecast.
The Company expects to continue achieving strong growth while further penetrating the large and rapidly expanding market for Business Process Outsourcing (BPO) services. Forrester Research forecasts the BPO space will have grown from $19 billion in 2004 to more than $145 billion in 2008, a Compounded Annual Growth Rate (CAGR) of 66%. Quintek has experienced a quarterly growth over the past several quarters.
"The Company has made progress within all of our targeted markets," stated Robert Steele, CEO of Quintek. "We continue to execute and deliver on long-term contracts with marquis customers and build relationships with our partners. Building upon the foundation we have created over the past 18 months, the Company should achieve critical mass, leading to profitability and an increase in shareholder value."
A summary of important business developments includes:
-- The development of Quintek's outsourced Accounts Payable (AP) service,
which can benefit almost any major corporation. As a result of increased
corporate reporting requirements spurred on by the Sarbanes-Oxley Act of
2002, demand is on the rise for solutions such as this.
-- Last fall Quintek entered into an agreement with a $3 billion provider
of industrial and institutional applications. Quintek provides a suite of
services that streamline and outsource this company's accounts payable (AP)
function.
-- The Company entered into an open agreement with Single Source Partners
(SSP) in April 2004 to advance sales in the mortgage industry.
-- Last fall, after identification by SSP, Quintek began providing
services to a Fortune 10 lending institution, with reported annual revenues
of over $20 billion. The Company has seen continued growth in revenues
within this account.
-- In July 2005, Quintek executed an Exclusive Sales and Marketing
Agreement with SSP targeting approximately $15 million in new business over
the next twelve months.
-- In the spring of 2004, the Company entered into an agreement with a
nationally recognized business solutions and overnight delivery company, to
provide outsourced services to their customers.
-- In February 2005, the Company began work on its first multi-year
agreement through the above mentioned relationship. Under this agreement
Quintek is providing services in Thousand Oaks, CA, for a leading life
sciences and biotechnology company.
-- Through a subcontracting agreement with a healthcare technologies
integrator, Quintek has been providing imaging service for over 12 months
for a major medical center in Los Angeles, CA.
Additionally, Quintek announced the creation of the Sapphire Consulting Services, Inc. business unit, a Supply Chain Management (SCM) consulting company that is a wholly owned subsidiary of Quintek. Sapphire is rapidly contributing to the overall growth of Quintek and it is expected to continue to add new customers and create new revenue channels. Sapphire has already identified a pipeline of potential business dollars with major customers across all markets that exceed $30 million.
Andrew Haag, Quintek CFO, commented, "We plan to capitalize on our success over the past year and a half by aggressively continuing to build our Company." He added, "As we grow we will expand our awareness with financial institutions and investors, with the goal of adding shareholder value."
About Quintek Technologies, Inc.
Quintek Technologies, Inc. (OTC BB:QTEK.OB - News), through its wholly owned subsidiaries Quintek Services, Inc. (QSI), and Sapphire Consulting Services, Inc., provides services to enable Fortune 500 and Global 2000 corporations to reduce costs and maximize revenues.
QSI delivers Business Process Outsourcing (BPO) services and solutions that enable companies to secure and manage their key data processing demands with optimal efficiency and minimal costs. As a next-generation technology company, Quintek is unhindered by outdated information technology systems, and thus is able to deploy best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a provider of IT market intelligence, forecasts 13% annual growth for the BPO industry through 2005, when the market is projected to reach $248 billion.
Sapphire Consulting Services, Inc. offers a broad range of supply chain management consulting services. Sapphire assists organizations to create a higher level of customer satisfaction, enhance supply chain capability and achieve consistent competitive advantage through reduced product cost, reduced inventory investment and improved supply chain security. A study by IDC found the SCM services market will expand from $26.1 billion in 2002 to $40.5 billion in 2007, representing a five-year compound annual growth rate (CAGR) of 9.2%.
For more information, visit http://www.quintek.com.
Safe Harbor Statement
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act''), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe'' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Quintek to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Quintek's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2004 and any subsequent reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Quintek assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, inability to timely develop of products or services, inability to deliver products or services when ordered, inability of potential customers to pay for ordered products or services, and political and economic risks inherent in domestic and international trade.
Contact:
CONTACTS:
Quintek Technologies, Inc.
Andrew Haag
Chief Financial Officer
(714) 848-7741, Ext. 14
Email Contact
Communications:
Cinapsys, Inc.
Mark Moline
(949) 497-6684
Email Contact
WSTM, pr and chart
bouncer?-> JWL,
PRCP on buyback pr
in CPICF @ .025
in CPICF @ .025
in CPICF @ .025
AI
